Icosavax is a Seattle-based biopharmaceutical company developing a vaccine candidate for respiratory syncytial virus and human metapneumovirus. The vaccine elicited a strong immune response against both viruses one month after vaccination in phase 2 trial.
Currently, there are no vaccines on the market for human metapneumovirus, and no combination vaccine for RSV, the drugmakers said.
The acquisition would put AstraZeneca in direct competition with GlaxoSmithKline and Pfizer, which both launched RSV vaccines in 2023.
The deal is expected to close in the first quarter of next year.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
